Blue Bear Ventures
VC Fund
San Francisco, United States
Blue Bear Ventures is a VC fund in San Francisco focused on Health Care and Biotechnology. Blue Bear Ventures (BBV) engages founders working on the frontiers of science and technology with the potential to solve some of the most pressing challenges we face in the world today.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Blue Bear Ventures invests in
Stages Blue Bear Ventures invests in
Countries Blue Bear Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Patrick Scaglia
|
|||
Alic Chen
|
|||
Deepak Gupta
|
|||
2 more contacts available
Investment Focus
Industry
- Health Care 3 (75%)
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Genetics 1 (25%)
- Software 1 (25%)
Stage
- Seed 3 (75%)
- Convertible Note 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Patrick Scaglia
Managing General Partner and Co-Founder
|
Managing General Partner and Co-Founder | Total investments: 0 | Find email | |
|
Alic Chen
Co-Founder & Partner
|
Co-Founder & Partner | Total investments: 0 | Find email | |
|
Deepak Gupta
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Unnatural Products
|
Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California. | $6M / Seed / Sep 18, 2019 | |
ImpriMed
|
ImpriMed is a company that creates individualized drug response prediction technology to help veterinarians fight lymphoma. The company's technology provides precision medicine techniques that allow veterinary oncologists to find appropriate anticancer drugs by developing a patient-derived database for pet cancer treatment that can eventuallybe translated into human cancer care, allowing doctors to decide on a final treatment regimen based on a data-driven prediction of response success in each individual patient's body. | $3.7M / Seed / Dec 18, 2018 | |
engageLively
|
Jupyter Hubs as a Service, with built in presentation, visualization, interaction, and a built in point-and-click chart editor | $50K / Convertible Note / Sep 30, 2018 | |
DNALite Therapeutics
|
DNALite Therapeutics, Inc. is an early-stage preclinical biotechnology company committed on bringing the next-generation of drugs to the gastrointestinal tract. Currently for some gastrointestinal diseases, such as colorectal cancer and Crohn's disease, complete or partial removal of the colon and/or rectum is the only treatment Our aimis to prevent not manage the progression of theses diseases. We are doing this by harnessing our proprietary technology to carry DNA to cells that drive these diseases. | $1.5M / Seed / Aug 08, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Blue Bear Ventures invest in?
Blue Bear Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Convertible Note stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Blue Bear Ventures?
Public channels for Blue Bear Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Blue Bear Ventures?
The team at Blue Bear Ventures includes Patrick Scaglia (Managing General Partner and Co-Founder), Alic Chen (Co-Founder & Partner) and Deepak Gupta (Co-Founder & Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
